Navigation Links
Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
Date:11/5/2007

chnology companies. For additional information about Paramount BioSciences, please visit http://www.paramountbio.com.

About TRB Chemedica

TRB Chemedica is a privately-owned Swiss pharmaceutical company with more than 20 years experience in research, development, manufacture and commercialization of innovative niche products in rheumatology, ophthalmology and neurology. TRB Chemedica has developed an expertise on the viscoelastic biopolymer, hyaluronic acid, manufacturing sterile finished products in its Swiss-based GMP facility. The company's product pipeline will help to fuel growth in each of the targeted therapeutic areas as well as introduce it into new areas of therapeutic focus. TRB Chemedica products are currently sold in more than 40 countries worldwide through wholly-owned subsidiaries, present in various countries in Europe, South America and Asia, and a growing network of licensing and distribution partners. For more information on TRB Chemedica visit the Company's web site at http://www.trbchemedica.com.

Caution Concerning Forward-Looking Statements. This press release might contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Lantibio's expectations and projections. Risks and uncertainties include success of clinical trials for Lantibio's products, intellectual property risks, need for additional financing or capital, ability to develop and successfully commercialize our products, ability to enter into licensing agreements, and the ability of the competition to render Lantibio's product candidates or technologies obsolete or noncompetitive. Lantibio assumes no obligation to updat
'/>"/>

SOURCE Lantibio, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... Richardson, Texas (PRWEB) October 20, 2014 ... today announced that a team from Iowa State University ... * design contest. Using a Convey HC-2ex, the team’s ... than 14 times faster than the second place finisher. ... academic world embarked upon the month long challenge, using ...
(Date:10/20/2014)... -- , A major pan-European survey into ... of care has revealed changing trends in many important ... provision of healthcare services across the continent. The results ... Gastroenterology (UEG), have been announced today and led to ... burden of GI disorders across Europe ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... A decade of helping scientists and clinicians understand life one cell ... ... time, HAYWARD, Calif., Feb. 6 This year ... technologies directly to the lab benches of thousands of,scientists and clinicians ...
... Feb. 5 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... Annual,BIO CEO and Investor Conference on Tuesday, February 12, ... is being held at the Waldorf-Astoria,Hotel in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... ... Expertise, OMAHA, Neb., Feb. ... has appointed David P.,Pauluzzi to its Board of Directors. Mr. Pauluzzi ... equity firm,specializing in the healthcare sector., Prior to his current ...
Cached Biology Technology:Guava Technologies Celebrates Tenth Anniversary 2Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference 2Transgenomic Appoints David Pauluzzi to Board of Directors 2Transgenomic Appoints David Pauluzzi to Board of Directors 3
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
... a long time that only 2% -- 3% of human ... genomes -- often referred to as junk DNA -- consists ... into DNA, and then reinserted into a new spot in ... these retroelements. Retroviruses can insinuate themselves into the host's DNA ...
... presented at the CIC bioGUNE hold at ... DNA chip concerning diagnosis and prognosis of ... normal, steatosis and NASH predisposed subjects. , ... of the liver of unknown etiology, characterized ...
... pioneering research into diseases such as Creutzfeld-Jakob Disease (CJD) and ... to a £300,000 grant from the Medical Research Council. , ... probable variant CJD (vCJD) in the UK. This is the ... with prions that is also responsible for the epidemic of ...
Cached Biology News:Chimp genome reveals a retroviral invasion 2Chimp genome reveals a retroviral invasion 3Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis 2
... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... can be used for gap filling, localized ...
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... System is the only PCR system that ... every time. It provides accuracy, consistency, and ... or the property of the DNA templates. ... Mix, a unique blend of thermostable enzymes ...
Biology Products: